# Atomo Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atomo-diagnostics

- Industry: Medical Devices & Equipment
- Headquarters: Sydney, Australia
- Website: www.atomodiagnostics.com
- Latest round: Seed (Jan 1, 2011)
- Investors on record: 1

## About

Atomo Diagnostics Limited develops innovative rapid diagnostic testing solutions focused on user-centered principles, enabling efficient healthcare diagnostics for both professionals and consumers worldwide.Founded in 2010 in Sydney, Australia, Atomo Diagnostics Limited specializes in rapid diagnostic testing solutions. Led by CEO John Kelly, the company has engaged in numerous funding activities, raising AUD 30 mn during its IPO in April 2020. Totaling 9 deals to date, the company operates in various global markets, enhancing access to healthcare services.Atomo Diagnostics Limited specializes in the development of innovative rapid diagnostic testing solutions designed around user-centered principles. Their core product offerings include the award-winning Galileo and Pascal platforms, which facilitate both professional and self-testing applications. These platforms are engineered to minimize user errors and enhance the accuracy and reliability of test results. The end use cases primarily target healthcare professionals and consumers who require efficient and accurate health diagnostics, particularly in decentralized testing environments. Atomo's technologies have been implemented globally, serving diagnostic companies across various markets, including North America, Europe, and Asia, thus broadening access to reliable healthcare solutions.In 2023, Atomo Diagnostics reported a revenue of AUD 1,712,777.90 and an EBITDA of AUD -5,470,840.40, generated through strategic partnerships with diagnostic companies that utilize its proprietary platforms for developing novel medical diagnostic products.Atomo Diagnostics Limited is focused on expanding its product line and market reach. Following its AUD 30 mn IPO on April 16, 2020, the company plans to launch additional products to enhance its diagnostic portfolio. Specific details regarding the new products and their anticipated release dates have not been disclosed. Additionally, Atomo aims to penetrate new markets, particularly in Asia and North America, to broaden its presence by 2025.

## Funding rounds

- Seed, Jan 1, 2011 — Sydney Angels

## Investors

- Sydney Angels (https://capitalatlas.ai/funds/sydney-angels) — Seed